Efficacy and safety of preoperative docetaxel chemotherapy and radical prostatectomy for untreated metastatic prostate cancer

In both cases, the prostate cancer disease was well controlled, and the tumor marker PSA was less than 0.2 ng/mL as shown below. No.1: December 2022 PSA 0.122 ng/mL (slow PSA increase, but PSA <0.2) No.2: January 2023 PSA 0.008 ng/mL (good control) Regarding adverse events, the patients presented only minor reversible events with usual surgical care and docetaxel chemotherapy, and no events unique to this clinical trial occurred.